NCT02144610.

Trial name or title	Efficacy and safety of AMG0001 in subjects with critical limb ischemia (AGILITY)
Methods	Phase III randomised parallel‐assignment quadruple‐blinded placebo‐controlled study
Participants	Participants with critical limb ischaemia
Interventions	HGF plasmid (AMG0001) or placebo
Outcomes	Time to major amputation, Major amputation and revascularisation, Complete ulcer healing, Ischaemic rest pain, Quality of life, Incident stroke and myocardial infarction, Primary bypass graft patency
Starting date	May 2014
Contact information	Richard J Powell; Dartmouth‐Hitchcock Medical Center
Notes

HGF: hepatocyte growth factor.
 PAD: peripheral arterial disease.